
Is Nano-Hydroxyapatite Toothpaste an Effective Fluoride Alternative? Dentists Weigh In
"As ingredient labels shift toward cleaner, fluoride-free formulas, one compound is taking center stage in modern oral care: nano-hydroxyapatite," Dr. Pia Lieb, DDS, cosmetic dentist and clinical assistant professor emerita at NYU College of Dentistry, explains. Marketed as a biomimetic, enamel-restoring alternative to fluoride, this ingredient has gained a loyal following, but does the science justify the hype?
To find out if nano-hydroxyapatite toothpaste is worth incorporating into your dental care routine, and if it's a viable replacement for fluoride toothpaste, we reached out to dentists for the potential benefits, side effects and their expert opinions.
What is nano-hydroxyapatite?
"Nano-hydroxyapatite is a synthetic calcium phosphate compound that's used in some oral care products, including toothpastes," explains Dr. Ada Cooper, consumer advisor and spokesperson for the American Dental Association, says. "[It] has a structure that is similar to hydroxyapatite found in enamel, and nHAP gets incorporated into the tooth structure preferentially in demineralized areas."
Nano-hydroxyapatite is also abbreviated as n-HA and n-HAp.
Dr. Royce Lai of King Village Dental adds that this is technically a two-part question, since "hydroxyapatite has been around for decades and has been studied for at least 20 years." Newer and less studied, nano-hydroxyapatite is a version of hydroxyapatite with small, rod-shaped particles.
"Hydroxyapatite is natural. It is a type of calcium that makes up bones and teeth," says Lai. "Nano-hydroxyapatite relates to the particle size. These are between 20 and 80 nanometers and are much smaller than the hydroxyapatite tubules that are a part of your teeth."
According to Dr. Daniela Eversgerd, a cosmetic dentist and the founder of Allure Dental, nano-hydroxyapatite was developed by NASA in the 1970s for astronauts dealing with bone and enamel loss during long periods of space travel. Since the early 1990s, it has been approved for oral care products in Japan.
Potential nano-hydroxyapatite toothpaste benefits
"Nano-hydroxyapatite doesn't just protect your teeth -- it helps rebuild them," says Dr. Catrise Austin, a cosmetic dentist, author of Gum Health Made Simple and host of the Let's Talk Smiles podcast. She lists the following as potential nano-hydroxyapatite benefits:
Enamel remineralization
Tooth sensitivity relief
Reduced bacterial adhesion
Whitening and gloss enhancement
"n-HA can actually fill microscopic cracks and help reverse or arrest early cavities," adds dentist Dr. Sandip Sachar.
Austin cites a 2019 study that found a 10% hydroxyapatite toothpaste is equivalent or non-inferior to fluoride toothpaste for preventing and remineralizing dental cavities (or caries) in children.
When it comes to teeth sensitivity, Lai cites a 2014 study concluding that 15% nano-hydroxyapatite helped sensitive teeth. "The particle size could get into space and work better than larger particles in micro-hydroxyapatite or fluoride," he explains. "The conclusion was that nano-hydroxyapatite could significantly reduce tooth sensitivity to hot and cold in two to four weeks of use."
Referencing an 18-month 2023 clinical trial finding that a 10% n-HAp toothpaste protected adult teeth from new cavities as well as a standard 1,450-ppm fluoride paste, Dr. Christopher Tolmie, DDS, MBA, states, "By patching enamel and calming swollen gums, nano-hydroxyapatite may cut off a hidden spark of chronic inflammation linked to heart disease and diabetes."
Since nano-hydroxyapatite toothpastes are fluoride free, Dr. Yenile Y. Pinto, DDS, functional and biomimetic dentist and founder of Deering Dental, adds, "It's also been shown to reduce sensitivity and strengthen the enamel surface without the risk of fluorosis." Fluorosis occurs when you get too much fluoride as a child, causing white or brown spots on the teeth. The CDC reports that fluorosis typically doesn't affect tooth function and isn't painful.
A 2020 systematic review of 32 studies concluded that "Nano-HA is a relatively novel material with outstanding physical, chemical, mechanical and biological properties that makes it suitable for multiple interventions. It outperformed most of the classic materials used in implantology and surgery, but it should be further investigated for bone engineering and caries prevention therapy."
HengleinA 2023 comprehensive review found that, while more long-term studies are needed to establish the safety of regular use, "Nanohydroxyapatite is a promising revolutionary material in the prevention of early carious lesion mainly due to a greater source of free calcium."
Ultimately, providing a 2021 review and 2022 scoping review, Cooper concludes, "Although there is some evidence that alternative ingredients, such as [nano] hydroxyapatite, prevent tooth decay by acting as a remineralizing or anti-cavity agent, the studies are preliminary. The only anti-cavity agent recognized by the Food and Drug Administration in its over-the-counter monograph is fluoride, a naturally occurring chemical."
Cooper adds that all toothpastes with the ADA Seal of Acceptance contain fluoride. The administration specifically recommends brushing your teeth twice a day with fluoride toothpaste and regularly visiting your dentist.
Potential nano-hydroxyapatite toothpaste side effects and EU restrictions
"According to a [2021] narrative review from Odontology, the official journal of the Society of the Nippon Dental University, so far, there have been no reports of adverse dental or systemic effects of HAP-containing toothpastes because HAP has an excellent biocompatibility," states Cooper.
According to Austin, the concern with nano-hydroxyapatite is that, because it's made of nanoparticles, some worry about how much might get absorbed into the body if regularly swallowed. "The European Commission's Scientific Committee raised concerns due to the lack of long-term safety data on ingestion, particularly in children," she says. This has led to temporary nano-hydroxyapatite restrictions (not a full-on banning) in Europe.
The European Scientific Committee deems nHA safe in toothpaste up to 29.5% and up to 10% in mouthwash, per Tolmie. However, he states, "Regulators still bar it from breath-spray products to avoid lung exposure, so stick to pastes and rinses."
Key concerns around nano-hydroxyapatite, according to Lieb, are:
Potential ingestion and systemic absorption, especially in nano form
Lack of long-term studies in humans on the cumulative effects
Unknown impact of inhalation from aerosol products (not toothpaste)
In terms of systemic absorption, Sachar specifies, "Because nano-hydroxyapatite particles are similar in composition to bone mineral, there has been some theoretical concern that if absorbed systemically, they could potentially contribute to unwanted calcifications in soft tissues (like blood vessels or kidneys)." However, she states that this is speculative and not supported by any current clinical evidence.Is nano-hydroxyapatite toothpaste only effective at 10%?
"Most clinical formulations of nHA range from 5%-15%, with 10% emerging as the benchmark concentration in several Japanese and European studies," answers Lieb. "This concentration has demonstrated reliable enamel restoration while maintaining product stability and usability."
However, she states that newer formulations are experimenting with lower concentrations and enhanced delivery systems (such as encapsulation or synergistic minerals), which may improve efficacy at reduced levels. "The effectiveness isn't just about percentage, it's also about particle quality and how it's delivered to the tooth surface," she explains.
Tolmie adds, "Effective repair starts as low as 5% and plateaus around 10-15%. Several studies show that 5% n-HAp can mend enamel dings, divots and dents in the teeth, with benefits leveling off somewhere between 10% and 15%. One review even noted that 5% sometimes beats 10% because fewer particles clump, making them easier to slip into enamel defects; hence, most US brands sit comfortably in the 5-10% sweet spot."
Should people replace fluoride toothpaste with nano-hydroxyapatite?
Eversgerd states that it all depends on each person's oral health needs. "Fluoride remains the gold standard for cavity prevention, supported by decades of large-scale, randomized controlled trials," she explains. "However, for patients seeking a fluoride alternative -- whether due to sensitivity, allergies, personal preferences or a desire for a biomimetic approach -- nano-hydroxyapatite provides a scientifically supported option."
According to the Academy of Biomimetic Dentistry, a biomimetic approach is one in which damaged teeth are restored using materials mimicking natural teeth in function, strength and appearance.
For high-risk patients, Eversgerd recommends fluoride, while she may recommend n-Ha to low-risk or fluoride-averse individuals.
Austin seconds this, but adds that she also recommends fluoride toothpaste to children with poor brushing habits or communities with limited dental access. "nHA is a great option, but it's not a one-size-fits-all replacement for fluoride -- yet," Austin says.
Lieb explains that nHA may also be a compelling alternative for patients with aesthetic concerns, such as whitening-induced sensitivity, and individuals in preventive care regimens post-restorative treatment.
Pinto agrees that it depends on the person, stating, "For most of my patients, especially those with low to moderate cavity risk, nano-hydroxyapatite is an excellent option; gentler on the mouth, less drying and effective at rebuilding early damage. For people with high cavity risk, fluoride might still be the best choice, at least short term. For my high-risk patients, I often recommend a combo toothpaste that includes both ingredients when appropriate." Ultimately, if a patient isn't high risk and has health or safety concerns about fluoride, she thinks hydroxyapatite is a great option.
When asked if there's a reason people should choose n-HAp over other anti-cavity toothpastes, Tolmie answers, "No, as long as patients are brushing their teeth with an anti-cavity toothpaste. There are differences in the way an n-HAp toothpaste and a fluoride toothpaste work to prevent decay, and some n-HAp toothpastes may feel smoother on the teeth. But anti-cavity toothpastes as a whole accomplish the same task. Do I wash a car with tap water or bottled water? We know that both of them get the job done."
What's most important, according to Tolmie, is that patients ensure they're not swallowing toothpaste.
What does the American Dental Association think? Cooper states that the ADA recommends brushing teeth twice daily for two minutes with fluoride toothpaste, as the naturally occurring mineral has been proven to remineralize weakened enamel and reverse early signs of tooth decay.
"Additionally, the fluoride you take in from drinking water and other beverages continues to provide a topical benefit because it becomes part of your saliva, constantly bathing the teeth and helping to rebuild weakened tooth enamel," Cooper further explains. "The best scientific evidence has shown that adding fluoride to community water supplies is safe and effective. This is backed by decades of research and recognized by more than 100 health organizations."
GoodboyDoes nano-hydroxyapatite toothpaste work?
All of the dentists we consulted agree that nano-hydroxyapatite toothpaste works, but in the right context and with the right product. It's also not a miracle cure and should not replace your entire oral care routine, dentist's recommendations or regular appointments. Plus, Eversgerd adds that more long-term, large-scale trials are needed to fully validate whether it's equal to fluoride in preventing cavities.
When asked if it's effective, Austin says, "Yes -- particularly for enamel remineralization and sensitivity. In my practice, I've seen patients who switched to nHA toothpaste experience noticeable improvements in comfort, plaque control and surface smoothness. But like any product, it works best when paired with consistent brushing, flossing and professional cleanings."
Pinto agrees and has also seen the results firsthand. "It helps remineralize enamel, soothe sensitivity and support a healthier oral microbiome, especially when paired with a good routine (good home hygiene, healthy diet, hydration and nasal breathing)," she explains, noting that it's not a miracle cure, but does offer many benefits.
On behalf of the ADA, Cooper echoes Eversgerd's earlier statement: "The use of nano-hydroxyapatite (nHAP) in over-the-counter products is growing and some evidence shows that nHAP may contribute to remineralization, but the evidence is fairly new and often ambiguous, especially regarding clinical indications. "
Do experts recommend nano-hydroxyapatite toothpaste?
All of the experts we consulted do recommend nano-hydroxyapatite toothpaste, but only for certain patients. After all, according to Austin, "Nearly half of US adults over 30 have some form of gum disease, and you can't out-toothpaste a bad hygiene routine." Brushing your teeth regularly, flossing and regularly visiting your dentist are still essential, no matter what toothpaste you use.
Though Lieb recommends nHA toothpaste for adult patients experiencing post-whitening sensitivity or early enamel erosion, low-caries risk individuals seeking natural alternatives and adults undergoing cosmetic dental work who want to protect their investment with gentle, remineralizing care, she doesn't recommend nano-hydroxyapatite for children with deciduous dentition.
"In my professional opinion, fluoride remains the safest and most effective option for all patients under 14," says Lieb. "Its protective effect during the development of permanent dentition is unmatched, and its caries-prevention record is well established."
Sachar states that she often recommends it for "patients seeking fluoride-free options, those with mild tooth sensitivity and for children at risk of swallowing fluoride toothpaste." However, she advises that patients with moderate to high cavity risk not fully abandon fluoride.
Again, it's important to note that the "ADA recommends that adults brush their teeth twice daily with fluoride toothpaste for at least two minutes each time, or as directed by a licensed dentist," according to Cooper. This is because the proposed benefits of nHAP are fairly new and ambiguous.
Getty Images
The bottom line
Though more research is needed, the dentists we consulted explained that nano-hydroxyapatite toothpaste can be an effective alternative to fluoride -- but only in the right context. The ADA doesn't recommend it. It's also not a miracle cure or a replacement for brushing regularly, flossing and professional dental appointments.
If you're considering nano-hydroxyapatite toothpaste, consult your dentist first before making the switch. They know your teeth best and will be able to help you find the best toothpaste for your smile.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
MEDIA ADVISORY: Baycrest Experts Available During AAIC® 2025 in Toronto
TORONTO, July 25, 2025 /CNW/ - From July 27 to 31, Toronto hosts the Alzheimer's Association International Conference® 2025 (AAIC®), the world's largest forum for dementia research. With Canada in the spotlight, Baycrest is recognized globally for its leadership in aging and brain health. Our scientists and experts are participating in the conference and available to support your coverage. This international gathering offers a timely opportunity to explore the growing impact of dementia on families, economies and health care systems, along with the latest advances in prevention, care, treatment and research. Dr. Howard ChertkowScientific Director, Baycrest's Kimel Family Centre for Brain Health & WellnessScientific Director, Canadian Consortium on Neurodegeneration in Aging (CCNA)Dr. Chertkow is a member of the AAIC Scientific Program Committee and one of Canada's most respected dementia researchers. He is available to speak on topics including dementia detection, prevention, treatment and Canada's role in the global research landscape. More Baycrest Experts You Can Speak With Dr. Adriana Shnall, Program Director, Baycrest Koschitzky Centre for Innovations in Caregiving, can speak to innovative tools supporting dementia caregivers, including those in rural and underserved communities. At AAIC, she is co-presenting on the use of virtual reality, AI and other strategies to better support families in community and long-term care settings. Dr. Allison Sekuler, President & Chief Scientist, Baycrest Academy for Research and Education is available to speak on the rising prevalence of dementia in Canada and its impact on individuals, families and the healthcare system. Dr. Nicole Anderson, Associate Scientific Director, Baycrest's Kimel Family Centre for Brain Health & Wellness, can discuss the latest in dementia prevention research, including evidence that nearly half of all cases may be preventable. Baycrest combines world-class care with cutting-edge research to help shape the future of aging and brain health. If you are working on AAIC-related coverage or broader dementia stories, our experts are available for interviews throughout the conference. Throughout the week, we will share updates with media highlighting key topics, research developments and expert perspectives from Baycrest. Please contact Natasha Nacevski-Laird, Media Relations Specialist at Baycrest, to schedule an interview. About Baycrest At Baycrest, our vision is a world where every older person lives with purpose, fulfilment and dignity. Baycrest is a global leader in aging and brain health innovation, with over 105 years of expertise in seniors' care and cutting-edge research. Baycrest has been Designated with Exemplary Status by Accreditation Canada, and drives industry-leading care and safety outcomes. As the home of the Centre for Aging + Brain Health Innovation (CABHI) powered by Baycrest, the Baycrest Academy for Research and Education (BARE) and the Canadian Consortium on Neurodegeneration in Aging, Baycrest is at the forefront of dementia research. Affiliated with the University of Toronto, Baycrest's training programs shape the future of care globally, while Baycrest Global Solutions extends its expertise to senior living and healthcare internationally. For more information, visit: SOURCE Baycrest View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
A science journal pulled a controversial study about a bizarre life form against the authors' wishes
NEW YORK (AP) — A microscopic discovery in a California lake sparked buzz and controversy more than a decade ago when it was first revealed. Scientists said they'd discovered bacteria that used the element arsenic — poisonous to life as we know it — to grow. If true, it expanded the possibilities for where life could exist on Earth — or on other worlds. Several research groups failed to replicate the results, and argue it's not possible for a living thing to use something so toxic to make DNA and proteins. Some scientists have suggested the results of the original experiments may have been skewed by undetected contaminants. On Thursday, the journal Science, which first published the research, retracted it, though not because of misconduct on the researchers' part. 'If the editors determine that a paper's reported experiments do not support its key conclusions, even if no fraud or manipulation occurred, a retraction is considered appropriate,' the journal's editor-in-chief Holden Thorp wrote in the statement announcing the retraction. The researchers disagree with the journal's decision and stand by their data. It's reasonable to pull a paper for major errors or suspected misconduct — but debates and disagreements over the findings are part of the scientific process, said study co-author Ariel Anbar of Arizona State University. 'One doesn't retract a paper because the interpretation is controversial, or even because most disagree with the interpretation,' wrote Anbar in an email. 'At least, that hasn't been the case until now.' Science has more frequently retracted papers for reasons beside fraud in recent years, said Thorp and Vada Vinson, Science's executive editor, wrote in a blog post. NASA helped fund the original work. The space agency's science mission chief Nicky Fox said in a statement that NASA does not support the retraction and encourages Science to reconsider. —- The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword


Medscape
18 minutes ago
- Medscape
CATALYST: A Novel Approach to Treating Diabetes
This transcript has been edited for clarity. Akshay B. Jain, MD:Welcome, from the ADA 85th Annual Sessions in Chicago. I'm endocrinologist Akshay Jain, from University of British Columbia in Vancouver. With us today is Dr Vivian Fonseca, professor of medicine at Tulane. Welcome, Dr Fonseca. Vivian Fonseca, MD: Hi there. Thank you for asking me to join you. Jain: Dr Fonseca, you're presenting the results of the CATALYST study. Tell us a little bit more about the study. Fonseca: The CATALYST study is a very novel approach to treating diabetes. We took people with uncontrolled diabetes despite taking many medications, including insulin, GLP-1 receptor agonists, dual agonists, SGLT2 inhibitors, and metformin. They also had many medications for hypertension. We asked the question as to whether cortisol was elevated and nonsuppressed in this population. We did a very simple overnight, 1-mg dexamethasone suppression test in a little over 1000 people. We were very surprised to find that 24% of them had a cortisol that did not fully suppress. They met the criteria for hypercortisolism as recommended by the European and the US endocrine societies today, at more than 1.8. Jain: That's a staggering number. Fonseca: That is a staggering number. It was quite a surprise to me and my colleagues. Jain: Once you identify these individuals, what's the next step for them? Fonseca: For the next steps, there is a range of things to do. If you identify hypercortisolism, you want to see whether there's an adrenal tumor or something like that. We did CT scans of the abdomen in that population, and one third of them had some abnormality. Not all of them had a tumor that was surgically resectable. Some had bilateral disease, and some just had thickening, which you would just wait and watch. Here, you have a population with hypercortisolemia at a higher rate than expected, with or without an abnormality on imaging. Some of them were surgically treatable, but for this particular study, we chose to take that group of people and treat them medically. There is a wide variety of medicines available for treating elevated cortisol, which have mainly been tested in Cushing syndrome. Mifepristone is a nonspecific steroid hormone receptor blocker that's known to block cortisol action and is approved for treating hyperglycemia in people with hypercortisolism. It was okay to actually test it in this population, so we did a randomized trial, randomizing those people with hypercortisolemia in a 2:1 ratio to mifepristone or placebo and following them for 24 weeks. Jain: What were the results? Fonseca: Again, another very surprising result. The A1c fell by 1.47%, almost 1.5% from the baseline of 8.5%. That is a very, very robust response. What I like about it is that this is not giving it to everybody with diabetes. You're using what I would call precision medicine. You find an abnormality, you treat that abnormality, and you get a very good result. There were a few other spinoff things. The weight fell significantly. The waist circumference declined significantly. There were also side effects that are consistent with the mifepristone side effect profile. The potassium fell. You get hypokalemia because the cortisol levels don't fall. They rise because you're blocking the receptor and you stimulate the mineralocorticoid receptor. The blood pressure went up a little bit, but it was still mostly at goal in most of the patients. You can treat that hypokalemia, so I won't go into that. We also had what we call glucocorticoid withdrawal syndrome. People on steroids who just stop, when you treat Cushing syndrome, or any of the medications for hypercortisolemia will give you a feeling of withdrawal of the steroid that you're used to. Those are to be expected. The side effect profile shows expected side effects in many people. But still, we can get around it and get a very good result on diabetes treatment. Jain: This is fascinating. We are unmasking hypercortisolemia as an underlying reason for insulin resistance. Fonseca: I wouldn't say unmasking. We are recognizing it in a novel way for the first time, and are able to treat people who we were throwing many drugs at [the problem] — wasting those drugs, if you ask me — when we were not treating the fundamental problem. Jain: When should clinicians think about this as an underlying issue? Fonseca: The way I translate every clinical trial, you do it for what the trial was done for. You have people who are uncontrolled, or you may say difficult to control, uncontrolled or on many medications. Often, you find comorbidities. They have had this problem for a while. Many of them have complications of diabetes, and a significant number had heart disease. You treat them with a very specific treatment, and you get a good result. Now, in some people the treatment may be surgical. You could use this drug or other drugs, and there are some new ones. This has become an important target for therapy, so we will see this approach. That also leaves the question as to [the fact that] there were 24% with this abnormality. What's happening in the other 75%? Maybe there are other abnormalities that we haven't recognized. I think you and I still have a large amount of work to do. Jain: We do indeed. Your target population was individuals with type 2 diabetes. Fonseca: Type 2 diabetes that was not controlled. Jain: Do you think this could be an underlying problem in type 1 diabetes as well? Fonseca: Hypercortisolism can occur in anybody. If you're finding many challenges in type 1 diabetes, you could do it. Obviously, people who are not doing well in their general health without diabetes could have hypercortisolism. This is not what we recognize as the textbook Cushing syndrome. These people did not have those features. The obesity was mild and low central. They had little features, but not the full-blown textbook description, which comes after many years of having very severe hypercortisolism. Jain: For those individuals who, say, are on birth control, would you then recommend doing a urine test? Fonseca: That's a very important question. We excluded those people from the study because you get a false elevation due to raising cortisol-binding globulin with estrogen. We did it in people who had a probability based on some anecdotal things and studies in Europe that were done before, and also excluding people who would have a false positive or a false negative, such as [those with] estrogen use. We don't know how to really identify those people well, without stopping the therapy. Jain: Any final key pearls of wisdom from this trial? Fonseca: I think, like anything that's new, it's exciting. Many of these people were very glad that we found an abnormality. I mean, it sounds bad, but they were blaming themselves, they were being labeled as noncompliant, and they were very frustrated with this. Jain: And the medication burden that they were facing. Fonseca: We actually withdrew a number of medications on several people. Jain: Great. Those are the results of the CATALYST trial. Thank you so much, Dr Fonseca, for joining. Fonseca: Thank you. It's a pleasure to be here.